In its ongoing mission to find the next Wegovy, Novo Nordisk has penned another partnership to seek out next-gen obesity treatments. This time, it's a $600 million biobucks pact with Flagship-founded ...

Owl butterflies amazingly ward off foes by disguising themselves as owls, thanks to wings that mirror the eyes of the woodland air predators. Flagship Pioneering is looking to build a new class of ...

May 9 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab signed a research tie-up with U.S. biotech firm Metaphore on Thursday to develop next-generation obesity drugs. Danish drugmaker Novo is trying ...

The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from ...

In a research collaboration that could bring in up to $600 million, Metaphore Biotechnologies Inc. has become the third Flagship Pioneering company this year to cut a development deal with mighty ...

CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel ...

Imitation is not just the sincerest form of flattery. When combined with machine learning, molecular mimicry is how Metaphore Biotechnologies designs novel treatments in autoimmune disease, ...

After two years of development at Flagship Pioneering, start-up Metaphore Biotechnologies emerged on May 16 with $50 million of series A funding. It plans to tackle autoimmune and metabolic diseases ...

The collaboration is a part of a broader strategy to combat cardiometabolic and rare diseases. Flagship Pioneering and Metaphore Biotechnologies, a Flagship-founded biotech company, announced a ...